Medicine useful in melasma

Randomised clinical trial of a pharmacopoeial preparation in the management of kalaf(melasma)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/10/046862

Enrollment

Registered

2022-10-27

Start date

Unknown

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma

Interventions

Intervention1: Mixture of qust e shireen and honey: Mixture of qust e shireen fine powder and honey for local application once a day for 1 hour Duration- 56 days Intervention2: Mixture of qust e shire

Eligibility

Inclusion criteria

Inclusion criteria: All skin types Who signed written consent form epidermal and mixed type melasma

Exclusion criteria

Exclusion criteria: Pregnant and lactating mothers Women on OCPs Patient on long term steroids Patient who are not willing to avoid cosmetics during the treatment time period

Design outcomes

Secondary

Measure	Time frame
3 D scannerTimepoint: 56 days;Melasma area and severity indexTimepoint: 56 days	—

Primary

Measure	Time frame
reduction in the pigmentationTimepoint: 56 days	—

Countries

India

Contacts

Public ContactDR ZAMIR AHMAD

ajmal khan tibbiya college

drzamiramrohi@gmail.com8475007594

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026